Everolimus alleviates cognitive dysfunction in 5×FAD mice by regulating mitochondrial function and oxidative stress.

Everolimus, a well-characterized inhibitor of the mammalian target of rapamycin (mTOR), has been extensively profiled in both preclinical and clinical studies. Accumulating evidence from recent studies suggests that mTOR inhibitors potentially possess the capacity to protect against various age-related diseases. Nevertheless, the impacts of Everolimus on cognitive function and the underlying mechanisms remain underexplored. In this study, we systematically evaluated the effects of varying doses of Everolimus (administered via intraperitoneal injection every other day for 8 weeks) on the cognitive ability of 5 × FAD mice. The learning and spatial memory of 5 × FAD mice were improved after Everolimus administration, with normal morphology and more pyramidal cells were detected in the hippocampi. Our findings suggest that Everolimus alleviates cognitive impairment in 5 × FAD mice through enhancing mitochondrial function, reducing oxidative stress, and improving energy metabolism within hippocampal tissues. Although these findings suggest an mTOR-dependent mechanism involving mitochondrial protection, the study did not investigate autophagy or mitophagy pathways, a limitation that should be addressed in future research. Collectively, these results demonstrate that Everolimus enhances cognitive function in 5 × FAD mice by promoting mitochondrial bioenergetics and mitigating oxidative stress, which positions it as a potential therapeutic candidate for cognitive dysfunction in Alzheimer's disease.